Is CNS Pharmaceuticals financially healthy?
Not really
CNS Pharmaceuticals earns only -1,049.7 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDA0.4 years
Cash vs. debt$7M vs. $328,571
Current ratio2.0×Short-term assets for each $1 of bills due within a year
Interest coverage-1,049.7×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about CNS Pharmaceuticals
Data as of Nov 13, 2026.